Creative Medical Technology Holdings Inc (NASDAQ:CELZ) — Market Cap & Net Worth
Market Cap & Net Worth: Creative Medical Technology Holdings Inc (CELZ)
Creative Medical Technology Holdings Inc (NASDAQ:CELZ) has a market capitalization of $2.45 Million ($2.45 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29745 globally and #5988 in its home market, demonstrating a -18.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Creative Medical Technology Holdings Inc's stock price $0.66 by its total outstanding shares 3696668 (3.70 Million). Review Creative Medical Technology Holdings Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
Creative Medical Technology Holdings Inc Market Cap History: 2015 to 2026
Creative Medical Technology Holdings Inc's market capitalization history from 2015 to 2026. Data shows change from $30.50 Billion to $2.45 Million (-58.43% CAGR).
Index Memberships
Creative Medical Technology Holdings Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #876 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2781 of 3165 |
Weight: Creative Medical Technology Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Creative Medical Technology Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Creative Medical Technology Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1207.58x
Creative Medical Technology Holdings Inc's market cap is 1207.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $37.43 Billion | $4.80K | -$2.66 Million | 7797659.06x | N/A |
| 2018 | $27.39 Billion | $124.40K | -$13.66 Million | 220195.44x | N/A |
| 2019 | $831.75 Million | $165.50K | -$8.48 Million | 5025.68x | N/A |
| 2020 | $513.84 Million | $164.50K | -$36.33 Million | 3123.63x | N/A |
| 2021 | $81.70 Million | $87.75K | $19.21 Million | 930.97x | 4.25x |
| 2022 | $14.09 Million | $88.60K | -$10.14 Million | 159.01x | N/A |
| 2023 | $17.04 Million | $9.00K | -$5.29 Million | 1893.52x | N/A |
| 2024 | $8.54 Million | $11.00K | -$5.49 Million | 776.30x | N/A |
| 2025 | $7.25 Million | $6.00K | -$6.00 Million | 1207.58x | N/A |
Competitor Companies of CELZ by Market Capitalization
Companies near Creative Medical Technology Holdings Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Creative Medical Technology Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Creative Medical Technology Holdings Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Creative Medical Technology Holdings Inc's market cap moved from $30.50 Billion to $ 2.45 Million, with a yearly change of -58.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.45 Million | -66.12% |
| 2025 | $7.25 Million | -15.15% |
| 2024 | $8.54 Million | -49.89% |
| 2023 | $17.04 Million | +20.97% |
| 2022 | $14.09 Million | -82.76% |
| 2021 | $81.70 Million | -84.10% |
| 2020 | $513.84 Million | -38.22% |
| 2019 | $831.75 Million | -96.96% |
| 2018 | $27.39 Billion | -26.81% |
| 2017 | $37.43 Billion | -97.35% |
| 2016 | $1.41 Trillion | +4536.36% |
| 2015 | $30.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Creative Medical Technology Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.45 Million USD |
| MoneyControl | $2.45 Million USD |
| MarketWatch | $2.45 Million USD |
| marketcap.company | $2.45 Million USD |
| Reuters | $2.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more